+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 12Years - 17Years
All Genders
ID07700758

Evaluation of Belzutifan Safety and Effectiveness in Adolescents with Advanced Solid Tumors

Led by Merck Sharp & Dohme LLC · Updated on 2026-10-30

15

Participants Needed

7

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating belzutifan as a treatment for adolescents aged 12 to 17 years who have locally advanced, unresectable, or metastatic solid tumors. This includes those with pheochromocytomaparaganglioma PPGL, wild-type gastrointestinal stromal tumors wtGIST, and localized tumors associated with Von Hippel-Lindau VHL disease. These rare and serious cancers often affect hormone-producing cells or the digestive tract and may be linked to genetic mutations. Participants will take belzutifan orally once daily, with the dose based on body weight 80 mg for those under 40 kg and 120 mg for those 40 kg or above. Treatment is planned for approximately two years. This study is a single-group, phase 2 trial focusing on the safety and tolerability of belzutifan in this adolescent population. During the trial, participants will be monitored for adverse events and treatment discontinuation related to side effects for up to five years. Researchers will also measure belzutifan levels in the blood and assess tumor response over this time. The study includes regular evaluations of safety, disease status, and drug effects to understand how well participants tolerate the treatment and how their tumors respond.

CONDITIONS

Brief Title

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

Research Team

T

Toll Free Number

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here